Scientists shed light on how serotonin works

Oct 05, 2010

Scripps Research Institute scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances. The new findings could have a profound effect on the development of new therapies for a number of disorders, including schizophrenia and depression.

The study was published in the October 6, 2010 issue of the Journal of Neuroscience.

has tremendous influence over several brain functions, including the control of perception, cognition, sleep, appetite, pain, and mood and mediates these effects through interactions with receptors located throughout the central and peripheral nervous systems.

"Our study shows that while both serotonin and hallucinogens act at the serotonin 2A receptor, serotonin utilizes a very specific pathway and its actions are independent of those produced by hallucinogens," said Laura Bohn, an associate professor on the Florida campus of The Scripps Research Institute. "Future drug discovery efforts to identify lead compounds for treatment of depression may consider focusing upon those that only engage that pathway. This work may also lend insight into the mechanisms that underlie the hallucinations that occur in schizophrenia."

This may be particularly important, Bohn said, for the treatment of depression because traditional therapies, which focus on elevating serotonin levels, can sometimes produce serious side effects such as a serotonin syndrome. This syndrome is often accompanied by hallucinations, and is especially serious when antidepressant treatments such as (SSRIs) are mixed with monoamine oxidase inhibitors (MAOIs).

The scientists' current study supports a long-standing hypothesis that hallucinations may arise from the metabolites formed from elevated serotonin levels. Since there is a difference in the way the two neurotransmitters signal, this may represent a means to preserve the effects of serotonin while preventing the adverse side effects caused by the metabolites.

Serotonin Versus Hallucinogens

The study, coauthored by Cullen Schmid, a graduate student in the lab, showed that serotonin signals through the serotonin 2A receptor by recruiting a regulatory protein called arrestin2, and that the actions of serotonin at the receptor are far different than those produced by hallucinogenic N-methyltryptamines, a class of naturally occurring substances found in several plants and in minute amounts in the human body and which includes the abused drug, DMT. The study found that the N-methyltryptamines activate the serotonin 2A receptor independently of arrestin2.

Both serotonin and the N-methyltryptamines produce what is known as a head twitch response in animal models, which indicates that the serotonin 2A receptor has been activated. Any interruption in the exclusive serotonin pathway prevents that behavioral response to serotonin, but has no effect on N-methyltryptamine-induced head twitches, indicating a distinct divergence in the signaling pathways utilized by these two neurotransmitters.

"Despite the fact that they activate the same receptor, serotonin leads to the assembly of a number of proteins associated with the receptor that the metabolites of serotonin do not produce," Bohn said. "But whether the lack of this complex formation is why compounds like DMT lead to hallucinations is not clear."

Bohn continues to investigate these and other questions.

Explore further: New research supporting stroke rehabilitation

More information: "Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor via an Arrestin2/Src/Akt Signaling Complex in Vivo," Journal of Neuroscience.

Related Stories

Some antipsychotic drugs may be missing their mark

Jan 01, 2008

Drugs that treat depression, schizophrenia and other psychotic conditions and that target a particular protein on brain cells might not be triggering the most appropriate response in those cells, new research suggests.

McGill study promises faster-acting anti-depressants

Sep 05, 2007

A McGill University study has found that a new class of drugs known as serotonin4 (5-HT4) receptor agonists may take effect four to seven times faster than traditional selective serotonin reuptake inhibitors (SSRIs). The study, l ...

Brain protein may be a target for fast-acting antidepressants

Feb 25, 2009

(PhysOrg.com) -- It takes weeks or months for the effect of most antidepressants to kick in, time that can feel like an eternity to those who need the drugs the most. But new research suggests that a protein called p11, previously ...

Sex differences in the brain's serotonin system

Feb 13, 2008

A new thesis from he Swedish medical university Karolinska Institutet shows that the brain’s serotonin system differs between men and women. The scientists who conducted the study think that they have found one of the reasons ...

Recommended for you

New research supporting stroke rehabilitation

8 hours ago

Using world-leading research methods, the team of Dr David Wright and Prof Paul Holmes, working with Dr Jacqueline Williams from the Victoria University in Melbourne, studied activity in an area of the brain ...

Team finds an off switch for pain

13 hours ago

In research published in the medical journal Brain, Saint Louis University researcher Daniela Salvemini, Ph.D. and colleagues within SLU, the National Institutes of Health (NIH) and other academic institutions have d ...

Brain researchers pinpoint gateway to human memory

15 hours ago

An international team led by researchers of the University of Magdeburg and the DZNE has successfully determined the location, where memories are generated with a level of precision never achieved before. ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.